Your browser doesn't support javascript.
loading
Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
Ramin, Cody; May, Betty J; Roden, Richard B S; Orellana, Mikiaila M; Hogan, Brenna C; McCullough, Michelle S; Petry, Dana; Armstrong, Deborah K; Visvanathan, Kala.
Afiliação
  • Ramin C; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
  • May BJ; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
  • Roden RBS; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
  • Orellana MM; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
  • Hogan BC; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
  • McCullough MS; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
  • Petry D; The Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Armstrong DK; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
  • Visvanathan K; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA. kvisvan1@jhu.edu.
Breast Cancer Res ; 20(1): 134, 2018 11 13.
Article em En | MEDLINE | ID: mdl-30424783
ABSTRACT

BACKGROUND:

Osteoporosis, an indicator of significant bone loss, has been consistently reported among older breast cancer survivors. Data are limited on the incidence of osteopenia, an earlier indicator of bone loss, and osteoporosis in younger breast cancer survivors compared with cancer-free women.

METHODS:

We prospectively examined bone loss in 211 breast cancer survivors (mean age at breast cancer diagnosis = 47 years) compared with 567 cancer-free women in the same cohort with familial risk for breast cancer. Multivariable-adjusted Cox proportional hazards models were used to estimate HRs and 95% CIs of osteopenia and/or osteoporosis incidence based on physician diagnosis.

RESULTS:

During a mean follow-up of 5.8 years, 66% of breast cancer survivors and 53% of cancer-free women reported having a bone density examination, and 112 incident cases of osteopenia and/or osteoporosis were identified. Breast cancer survivors had a 68% higher risk of osteopenia and osteoporosis compared to cancer-free women (HR = 1.68, 95% CI = 1.12-2.50). The association was stronger among recent survivors after only 2 years of follow-up (HR = 2.74, 95% CI = 1.37-5.47). A higher risk of osteopenia and osteoporosis was also observed among survivors aged ≤ 50 years, estrogen receptor-positive tumors, and those treated with aromatase inhibitors alone or chemotherapy plus any hormone therapy relative to cancer-free women.

CONCLUSIONS:

Younger breast cancer survivors are at higher risk for osteopenia and osteoporosis compared to cancer-free women. Studies are needed to determine effective approaches to minimize bone loss in this population.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteoporose / Neoplasias da Mama / Antineoplásicos Hormonais / Inibidores da Aromatase / Sobreviventes de Câncer Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteoporose / Neoplasias da Mama / Antineoplásicos Hormonais / Inibidores da Aromatase / Sobreviventes de Câncer Idioma: En Ano de publicação: 2018 Tipo de documento: Article